![]() The Chromium X series is available now for pre-order and is expected to ship later this quarter. The Chromium X Series is compatible with all of the company’s existing low throughput and standard single cell assays and is supported by the 10x Genomics Cloud Analysis offering for data management, analysis and collaboration. ![]() “The high-scale, high-resolution era is coming and we need high throughput products capable of delivering ‘routine’ big scale translational experiments, like the new Chromium X promises to do.” “We will need to analyze cells at larger scale and the highest resolution possible to answer the many questions that we have as scientists,” said Luciano Martelotto, Scientific Director of Harvard Medical School's Single-Cell core lab. “We are offering scientists a state-of-the-art instrument with immense flexibility to power a generation of new discoveries that will advance human health.” “The new Chromium X Series is a milestone for us and our most ambitious project to date,” said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. The product accelerates discoveries in areas including drug and CRISPR screens, large-scale translational studies, cell mapping, antibody discovery and biomarker identification. The Chromium X, which has been in development for more than two years, delivers extensive scale and operational simplicity for single cell analysis. It also includes the Chromium iX, an instrument capable of running experiments for tens of thousands of cells seamlessly upgradable to the X as scientists expand their research projects.ġ0x Genomics now offers a vast range of single cell analysis technologies from entry level with its existing Chromium Controller to massively large-scale experiments, giving scientists a path to cost effectively expand from standard experiments to higher throughput projects, all available in one place. The new Series comprises the Chromium X, the company’s most powerful instrument yet that delivers routine million cell experiments down to two cents per cell, an industry first. PLEASANTON, Calif., J(GLOBE NEWSWIRE) - Building on its industry leading position in single cell analysis, 10x Genomics (NASDAQ: TXG) today announced commercial availability of its new Chromium X Series, a next-generation platform for single cell analysis.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |